威領股份(002667.SZ):5%股東終止協議轉讓公司股權
格隆匯5月19日丨威領股份(002667.SZ)公佈,公司於2024年9月4日披露了《關於持股5%以上股東協議轉讓公司部分股權的提示性公吿》。2024年11月16日披露了《關於持股5%以上股東協議轉讓公司部分股權的進展公吿》。楊永柱先生擬通過協議轉讓方式向百瑞坤投資管理(北京)有限公司-百瑞金鈎私募證券投資基金轉讓其所持公司12,142,790股無限售流通股,佔公司總股本的5.01%。公司於近日接到楊永柱先生的通知,楊永柱先生與百瑞坤投資管理(北京)有限公司-百瑞金鈎私募證券投資基金簽署了《終止協議》,終止本次股權轉讓事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.